Crinetics Pharmaceuticals, Inc.
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
Last updated:
Abstract:
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Status:
Grant
Type:
Utility
Filling date:
13 Dec 2019
Issue date:
8 Sep 2020